A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

The aim of this study is to define the maximum tolerated dose (MTD), safety, pharmacokinetics (PKs) and efficacy of ispinesib (SB-715992) in combination with docetaxel. Patients with advanced solid tumours were treated with ispinesib (6–12 mg m(−2)) and docetaxel (50–75 mg m(−2)). Docetaxel was admi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Blagden, S P, Molife, L R, Seebaran, A, Payne, M, Reid, A H M, Protheroe, A S, Vasist, L S, Williams, D D, Bowen, C, Kathman, S J, Hodge, J P, Dar, M M, de Bono, J S, Middleton, M R
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2008
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2266864/
https://ncbi.nlm.nih.gov/pubmed/18319713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604264
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados